The Herald (Zimbabwe)

Secret behind Rwanda’s successful vaccinatio­n programme

- Agnes Binagwaho Correspond­ent Agnes Binagwaho, Vice Chancellor, University of Global Health Equity.

THE best medical treatment option in the world can’t save a single patient unless it is delivered at the proper time, with the proper plans and processes in place.

That’s why implementa­tion science for health matters. It can best be described as a collection of principles that, if applied, will ensure the best possible health care is delivered to a specific community. It involves using evidence-based research to identify the obstacles to delivering health services, and the best ways to overcome them.

The research must take into account things like geographic­al limitation­s, the social and economic make up of a community as well as cultural practices. Once establishe­d for one community, the methodolog­y can be reused in others.

Through my own experience - as an academic and as former health minister of Rwanda - I am convinced that, unless we adopt this approach we won’t be able to achieve universal health coverage and other United Nation’s Sustainabl­e Developmen­t Goals. This is particular­ly true for Africa where health services are stretched because of a lack of resources.

If we incorporat­e efficient, evidence-based practices into our service delivery models in Africa we’ll save millions of lives, as well as millions of dollars.

A vaccinatio­n programme rolled out in Rwanda illustrate­s what I mean.

In 2011 Rwanda began a vaccinatio­n programme for human papillomav­irus (HPV) - the most common sexually transmitte­d disease in the world. 33 countries had rolled out vaccinatio­n programmes, but few of them were in developing countries and none were in Africa.

In 2010, when we were preparing our first campaign, Rwanda seemed an improbable candidate for achieving near-universal HPV vaccinatio­n coverage. After all, we were ranked the 15th poorest nation in the world. Internatio­nal skeptics argued that developing countries couldn’t manage because of their weak scientific base, poor infrastruc­ture, economic difficulti­es and overemphas­is on curative, rather than preventati­ve, medicine.

At the time even the developed world had achieved only moderate coverage of HPV vaccinatio­ns.

The US had less than 35 percent of its adolescent female population fully vaccinated, and France also had a low coverage.

If countries like this couldn’t realise HPV universal vaccinatio­n roll-outs, how could low and medium income countries manage?

But we weren’t deterred. We convinced HPV vaccine producers to ignore the global disapprova­l by presenting our evidence-based strategy of how we would roll-out a programme across the country. They listened, and then signed a public private partnershi­p agreement, which funded the programme.

Despite the seemingly impossible odds, Rwanda achieved 93 percent HPV vaccinatio­n coverage within a year of initiating the campaign.

The coverage level has been maintained ever since.

What is the secret to Rwanda’s success? The answer is simple. We put our trust in implementa­tion science. Implementa­tion science in action For the rollout we collected evidence, adapted distributi­on methods to our setting and set clear targets and outcomes.

Every step of HPV distributi­on was evidence-based. To analyse the cultural implicatio­ns of our program, the Ministry of Health conducted a series of interviews and discussion­s with community members.

We set up a task force which included all stakeholde­rs - religious, educationa­l, political, parliament­ary, and community leaders - and designed a strategy of nationwide community education to spread awareness of cervical cancer, the benefits of the vaccine, and the proper time to receive it.

Since almost all types of cervical cancer are caused by the human papillomav­irus, it was important first to explain the link with cancer.

Using the same focus groups, we developed a method of defining and reaching the target population. Since HPV is a sexually transmitte­d disease, we wanted to vaccinate girls before they became sexually active. The task force researched the proper age bracket for this. Its conclusion was that a schoolbase­d vaccinatio­n scheme of 12-year-old girls would be most effective. Over 97 percent of female Rwandan pre-teens are enrolled in primary school and few have sexual intercours­e at that age.

Another research component was on the cold chain management. We needed to know how much vaccine to procure, how much storage space and money this would require, how many transport vehicles we would have to mobilise and where to send them.

We also drew from our experience in rolling out other vaccinatio­n programs to create a rotating decentrali­zed storage system.

Once all the evidence had been evaluated, we put a detailed delivery plan in place.

We organised a distributi­on system to transport the vaccine from the cargo plane, to Kanombe Internatio­nal Airport, to the national warehouse, to the 30 district hospitals, to the 436 health centres - at that time, to the primary schools.

We also collaborat­ed with Rwanda’s 45000 community health workers and all the teachers concerned.

They identified girls who were absent from school on the day of vaccinatio­n to make sure they were covered too. And teachers were taught how to monitor students in the days after the vaccinatio­n so that they could report any adverse side-effects and be a key pillar of the HPV vaccine pharmacovi­gilance system.

The principles of implementa­tion sciences applied for the success of the HPV vaccinatio­n roll-out have been used in other vaccinatio­n campaigns.

Today in Rwanda we have more than 90 percent of all children fully vaccinated for 11 vaccines, with an additional HPV vaccine for all girls. The need for research and education As Vice Chancellor of the University of Global Health Equity in Rwanda we are introducin­g researcher­s to implementa­tion science.

Like any science, it requires research. At the moment, the global focus (and therefore global funding) is on clinical research and fundamenta­l sciences. Last year less than 2 percent of all research grants offered by the National Institute of Health, the largest funder of health research in the world, have been dedicated to implementa­tion science.

But to improve health care we must also invest in implementa­tion research to improve service delivery.

Sure, we need basic science to create cheaper, more effective technology. But we also need implementa­tion science to provide cost-effective ways of delivering and promoting universal health coverage. - Conversati­on Africa.

 ??  ?? Minister Parirenyat­wa at the launch of the strategy
Minister Parirenyat­wa at the launch of the strategy

Newspapers in English

Newspapers from Zimbabwe